Last $35.09 USD
Change Today +0.08 / 0.23%
Volume 309.8K
ACOR On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 2:06 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

acorda therapeutics inc (ACOR) Snapshot

Open
$35.08
Previous Close
$35.01
Day High
$35.65
Day Low
$34.64
52 Week High
01/13/15 - $45.45
52 Week Low
08/1/14 - $28.26
Market Cap
1.5B
Average Volume 10 Days
967.1K
EPS TTM
$0.69
Shares Outstanding
42.6M
EX-Date
--
P/E TM
51.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for ACORDA THERAPEUTICS INC (ACOR)

acorda therapeutics inc (ACOR) Related Businessweek News

No Related Businessweek News Found

acorda therapeutics inc (ACOR) Details

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system in the United States. The company’s products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; Zanaflex Capsules and Zanaflex tablets, a short-acting drug for the management of spasticity, a symptom of central nervous system disorders; and Qutenza, a dermal patch for the management of neuropathic pain. It is also involved in developing Diazapam Nasal Spray for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase III clinical development program preparations for post-stroke deficits; NP-1998, a topical solution that is in phase III clinical trial for the treatment of neuropathic pain; AC105, which is in Phase II clinical trials for the treatment of SCI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for the treatment of injuries to the brain and spinal cord, as well as other neurotraumatic indications. The company was founded in 1995 and is headquartered in Ardsley, New York.

489 Employees
Last Reported Date: 02/27/15
Founded in 1995

acorda therapeutics inc (ACOR) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $720.8K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $193.9K
Chief of Business Operations
Total Annual Compensation: $312.7K
General Counsel, Corporate Secretary and Pres...
Total Annual Compensation: $517.7K
Chief Medical Officer
Total Annual Compensation: $418.5K
Compensation as of Fiscal Year 2013.

acorda therapeutics inc (ACOR) Key Developments

Acorda Therapeutics, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 11:00 AM

Acorda Therapeutics, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 11:00 AM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Ron Cohen, Founder, Chief Executive Officer, President and Director.

Acorda Therapeutics, Inc. Announces Unaudited Consolidated Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014; Reports Asset Impairment for the Fourth Quarter Ended December 31, 2014

Acorda Therapeutics, Inc. announced unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net income of $0.3 million, or $0.01 per diluted share against net income in the same quarter of 2013 was $6.2 million, or $0.15 per diluted share a year ago. Non-GAAP net income was $19.7 million, or $0.46 per diluted share against non-GAAP net income of $18.9 million, or $0.45 per diluted share a year ago. Total Revenue was $117.872 million against $92.593 million a year ago. Operating income was $1.169 million against $12.749 million a year ago. Loss before income taxes was $2.693 million compared to income before income taxes of $12.630 million a year ago. For the full year, the company reported net income of $17.7 million, or $0.42 per diluted share against net income for the full year 2013 was $16.4 million, or $0.39 per diluted share a year ago. Non-GAAP net income was $73.8 million, or $1.74 per diluted share against non-GAAP net income for the full year ended December 31, 2013 of $52.4 million, or $1.26 per diluted share. Total revenues were $401.480 million against $336.430 million a year ago. Operating income was $36.391 million against $30.365 million a year ago. Income before income taxes was $28.009 million compared to $28.863 million a year ago. For the fourth quarter ended December 31, 2014. the company reported asset impairment of $6.991 million.

Acorda Therapeutics, Inc., Q4 2014 Earnings Call, Feb 12, 2015

Acorda Therapeutics, Inc., Q4 2014 Earnings Call, Feb 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACOR:US $35.09 USD +0.08

ACOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ACADIA Pharmaceuticals Inc $38.13 USD -0.10
Depomed Inc $23.61 USD +0.55
Durect Corp $1.22 USD +0.19
Impax Laboratories Inc $39.82 USD -0.63
Isis Pharmaceuticals Inc $67.39 USD +0.59
View Industry Companies
 

Industry Analysis

ACOR

Industry Average

Valuation ACOR Industry Range
Price/Earnings 81.5x
Price/Sales 3.5x
Price/Book 2.6x
Price/Cash Flow 80.3x
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACORDA THERAPEUTICS INC, please visit www.acorda.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.